4.8 Article

FAAH genetic variation enhances fronto-amygdala function in mouse and human

Journal

NATURE COMMUNICATIONS
Volume 6, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/ncomms7395

Keywords

-

Funding

  1. NIH [MH079513, MH060478, NS052819, GM07739, EY007138, DA017259]
  2. Pritzker Neuropsychiatric Disorders Research Consortium
  3. NewYorkPresbyterian Hospital Youth Anxiety Centre
  4. Brain and Behavior Research Foundation
  5. DeWitt-Wallace Fund of the New York Community Trust
  6. Canadian Institutes of Health Research
  7. Alberta Innovates Health Solutions

Ask authors/readers for more resources

Cross-species studies enable rapid translational discovery and produce the broadest impact when both mechanism and phenotype are consistent across organisms. We developed a knock-in mouse that biologically recapitulates a common human mutation in the gene for fatty acid amide hydrolase (FAAH) (C385A; rs324420), the primary catabolic enzyme for the endocannabinoid anandamide. This common polymorphism impacts the expression and activity of FAAH, thereby increasing anandamide levels. Here, we show that the genetic knock-in mouse and human variant allele carriers exhibit parallel alterations in biochemisty, neurocircuitry and behaviour. Specifically, there is reduced FAAH expression associated with the variant allele that selectively enhances fronto-amygdala connectivity and fear extinction learning, and decreases anxiety-like behaviours. These results suggest a gain of function in fear regulation and may indicate for whom and for what anxiety symptoms FAAH inhibitors or exposure-based therapies will be most efficacious, bridging an important translational gap between the mouse and human.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available